Cargando…

FRI055 LYNC-LD: Prospective Multicenter Natural History Study Of Lipodystrophy Syndromes To Determine Prevalence, Incidence And Predictors Of Diabetes And Severe Hypertriglyceridemia, And Their Complications

Disclosure: M.C. Foss de Freitas: Advisory Board Member; Self; PTC Therapeutics. D.S. Rosenberg: None. M. Celik Guler: None. M. Yosef: None. S. Khalatbari: None. R. Carman: None. A. DillGomes: None. M. Ashmus: None. C. Spino: None. B. Akinci: Advisory Board Member; Self; Aegerion Pharmaceuticals, Re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Foss de Freitas, Maria Cristina, Rosenberg, Drake Stanton, Guler, Merve Celik, Yosef, Matheos, Khalatbari, Shoukoufeh, Carman, Richison, DillGomes, Anabela, Ashmus, Michelle, Spino, Cathie, Akinci, Baris, Brown, Rebecca J, Oral, Elif A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Adipose Tissue, Appetite, & Obesity
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555319/ http://dx.doi.org/10.1210/jendso/bvad114.066

Ejemplares similares

MON-101 The LD Lync Study: Natural History Study of Lipodystrophy Syndromes: Early Lessons from the Pilot Data
por: Jalal Eldin, Abdelwahab, et al.
Publicado: (2019)

FRI059 Long-term Follow-up On Partial Lipodystrophy Treated With Leptin Receptor Agonist Mibavademab(REGN4461)
por: Foss de Freitas, Maria Cristina, et al.
Publicado: (2023)

Abnormal Non Esterified Fatty Acid Suppression After a Mixed Meal Test in Patients With Partial Lipodystrophy
por: de Freitas, Maria Cristina Foss, et al.
Publicado: (2021)

Untangling the Heterogeneity of Acquired Generalized Lipodystrophy
por: Cavdar, Umit, et al.
Publicado: (2021)

Inhibition of Angiopoietin-Like 3 (ANGPTL3) Reduces Adipose Tissue Insulin Resistance in Patients With Familial Partial Lipodystrophy
por: de Freitas, Maria Cristina Foss, et al.
Publicado: (2021)

OR33-02 The Treatment of Partial Lipodystrophy in the Setting of Neutralizing Antibody Against Metreleptin with Leptin Receptor Agonist REGN4461
por: Akinci, Baris, et al.
Publicado: (2020)

FRI028 Multiple Symmetric Lipomatosis As A Model For Understanding The Importance Of Mitochondria Function On Adipose Tissue Biology
por: Foss de Freitas, Maria Cristina, et al.
Publicado: (2023)

RF24 | PSUN126 A Very-Low Calorie Diet Can Reduce Insulin Resistance and Cause Remission of Diabetes Mellitus and Hypertriglyceridemia in a Patient With Familial Partial Lipodystrophy Type 2
por: De Freitas, Maria Foss, et al.
Publicado: (2022)

ODP008 Nonalcoholic Fatty Liver Disease (NAFLD) Impacts Weight Loss after Bariatric Surgery
por: Abu-Rumaileh, Mohammed, et al.
Publicado: (2022)

SUN-607 Iron Parameters in Patients with Partial Lipodystrophy and Impact of Metreleptin Therapy
por: Boutros, Sabine, et al.
Publicado: (2020)

SUN-593 Variants in Known Monogenic Causal Genes of Hypertriglyceridemia Are Not Major Contributors for Hypertriglyceridemia in Lipodystrophy Due to a LMNA Mutation
por: Ueda, Masako, et al.
Publicado: (2020)

SUN-600 Presence of LMNA p.R582H Pathogenic Variant in Homozygous State Demonstrates Gene Dosage Effect on the Severity of Fat Loss in Lipodystrophy
por: Soyaltin, Utku Erdem, et al.
Publicado: (2020)

FRI018 A Novel Truncating Variant Of EBF2 Disrupts Human Adipocyte Differentiation In Lipodystrophy Syndromes: An Example Of A Discovery From A Clinical Translational Pipeline
por: Foss de Freitas, Maria Cristina, et al.
Publicado: (2023)

FRI058 Treatment With Mibavademab, A Novel Leptin Receptor Agonist, Is Associated With Improvement In Metabolic Parameters In Individuals With Generalized Lipodystrophy
por: Olenchock, Ben, et al.
Publicado: (2023)

FRI057 Drug Concentrations And Dosing Considerations For Mibavademab, A Novel Leptin Receptor Agonist, In Individuals With Generalized Lipodystrophy
por: Mendell, Jeanne, et al.
Publicado: (2023)

SAT674 Lipodystrophy: A Hidden Culprit In Uncontrolled Diabetes
por: Sayed, Farah El, et al.
Publicado: (2023)

Leptin Decreases Energy Expenditure but Increases Thyroid Hormone in Patients With Lipodystrophy
por: Quaye, Emmanuel, et al.
Publicado: (2021)

Impact of Morbid Obesity on Patients With Hypertriglyceridemia Induced Acute Pancreatitis
por: Pudasaini, Garima, et al.
Publicado: (2021)

Novel Heterozygous LMNA Variants Causing Familial Partial Lipodystrophy, Dunnigan Variety
por: Wadhwa, Akhilesh, et al.
Publicado: (2021)

FRI054 Partial Lipodystrophy As A Manifestation Of Autoimmune Polyglandular Syndrome 1
por: Agarwal, Shubham, et al.
Publicado: (2023)

Metabolic Improvements After Gastric Sleeve Surgery in a Patient With Familial Partial Lipodystrophy
por: Niaz, Azra, et al.
Publicado: (2021)

FRI056 Effect Of 48 Hour Of Metreleptin In Humans With Lipodystrophy During Controlled Feeding
por: Bukhari, Khulood M, et al.
Publicado: (2023)

SAT676 Severe Recurrent Pancreatitis In A Familial Partial Lipodystrophy Patient On Metreleptin
por: Sargin, Pinar, et al.
Publicado: (2023)

MON-100 Unique miRNA Signature in HIV Lipodystrophy with Reduced Adipose Dicer Expression
por: Srinivasa, Suman, et al.
Publicado: (2019)

SUN-610 Acquired Generalized Lipodystrophy: A Rare Side Effect of PD1-Inhibitor Therapy
por: Shah, Amy, et al.
Publicado: (2020)

RF12 | PSUN80 A Novel DXA Algorithm to Aid in the Diagnosis of Familial Partial Lipodystrophy
por: Harris, Charles, et al.
Publicado: (2022)

MON-590 Presence of Diabetes Diminishes the Ultimate Weight Loss After Bariatric Surgery
por: Luo, Yingying, et al.
Publicado: (2020)

PSUN81 A novel case of congenital generalized lipodystrophy (CGL) with no genetic abnormalites in the AGPAT2, BSCL2, CAV1, and CAVIN1 genes.
por: Mericq, Veronica, et al.
Publicado: (2022)

FRI069 Treatment With Mibavademab, A Novel Leptin Receptor Agonist, Is Associated With Improvement In Weight And Associated Comorbidities In Congenital Leptin Deficiency
por: Ozsu, Elif, et al.
Publicado: (2023)

MON-121 Pain Is a Major Driver of Quality of Life and Psychoemotional Health in Lipodystrophy Syndromes
por: Eldin, Abdelwahab Jalal, et al.
Publicado: (2020)

PSUN100 What Determines Leptin Levels: Moving Beyond Fat Mass
por: Rosenberg, Drake, et al.
Publicado: (2022)

MON-104 Defining the Contribution of Weight to the Extent of Metabolic Disease in FPLD: Insights from a Retrospective "Matched" Case-Control Study
por: Koo, Eden, et al.
Publicado: (2019)

SAT-110 Long-Term Impact of Gastric Bypass versus Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease: Retrospective Observations from Michigan Bariatric Surgery Cohort
por: Haddad, Raad, et al.
Publicado: (2019)

SAT-LB020 Use of Ultrasound to Characterize Abdominal Adipose Tissue Distribution and Its Impact on Metabolic Syndrome
por: Cuatrecasas Cambra, Guillem, et al.
Publicado: (2019)

MON-099 Age-Related Differences in Appetite Regulation among Adults with Obesity: More Than Just Hunger and PYY and Ghrelin? Oh My!
por: Iwamoto, Sean, et al.
Publicado: (2019)

MON-114 Effect of Selective Mineralocorticoid Receptor Antagonist on liver Fat and Metabolism in Patients with Type 2 Diabetes: A Randomized Controlled Trail
por: Kistorp, Caroline, et al.
Publicado: (2019)

MON-092 Role of Genetic Variants of NNMT rs694539 and rs1941404, FTO rs1421085 and Irx3 rs3751723 Polymorphisms on Resting Energy Expenditure and BMI
por: Bañales Luna, Maciel, et al.
Publicado: (2019)

MON-113 Taste Sensitivity is Related to Incretin Response to Oral Glucose Challenge, Dietary Habits and Body Composition: A Novel Link with Energy Metabolism
por: Dagdelen, Selcuk, et al.
Publicado: (2019)

MON-106 Prevalence of Abdominal Obesity According to Different Cutoff Points in the Peruvian Population Living at Different Altitudes
por: Pajuelo-Ramirez, Jaime, et al.
Publicado: (2019)

MON-115 Acute BAT Activation Improves Glucose Tolerance and Beta-Cell Secretion and Facilities Lipid over Glucose Utilization in Obese Metabolically Healthy Males
por: Bertozzi, Beatrice, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i68pkn7r98jgtg6me8908p3s8e